12 Oversold Blue Chip Stocks to Buy According to Analysts

Page 6 of 6

6. Abbott Laboratories (NYSE:ABT)

On April 10, Reuters reported that a jury in Chicago ruled that Abbott Laboratories (NYSE:ABT) must pay $70 million in damages to a group of families. The families had accused the company of failing to warn that its formula for premature infants could cause a potentially deadly bowel disease, according to a company spokesperson.

The decision followed a lengthy trial. It is one of many cases, with hundreds of lawsuits claiming that Abbott’s cow milk-based formula products for preterm infants are linked to necrotizing enterocolitis, or NEC. In this case, four families combined their lawsuits into a single trial. The jury found the company liable on April 9 and awarded $53 million in compensatory damages to the families, the spokesperson said. They returned the next day to consider punitive damages and awarded an additional $17 million.

On April 8, 2026, Barclays raised its price target on Abbott to $144 from $142 and maintained an Overweight rating after updating its model to reflect the Exact Sciences acquisition. Meanwhile, Evercore ISI analyst Vijay Kumar lowered the firm’s price target to $134 from $138 and kept an Outperform rating as part of its Q1 preview for medical technology and life science tools.

Last month, Abbott and Flatiron Health announced the integration of Abbott’s Precision Oncology portfolio into Flatiron’s OncoEMR platform, enabling providers to order tests and receive results directly within their clinical workflow. The integration includes tests such as Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard, and expands access across Flatiron’s network of more than 1,600 cancer care centers and 4,700 providers.

Abbott Laboratories (NYSE:ABT) develops and sells healthcare products globally.

While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 Oversold Blue Chip Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.

Page 6 of 6